Key Developments For Isis Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc. (ISIS.O) (Consolidated Issue listed on NASDAQ Global Market)
Isis Pharmaceuticals Reaffirms FY 2009 Earnings Guidance
Isis Pharmaceuticals announced that it is confident that it will meet its fiscal 2009 financial guidance of more than $145 million of net income and a net operating loss in the low to mid $20 million range. According to Reuters Estimates, analysts are expecting the Company to report net profit of $151.40 million and EBIT of $(24) million for fiscal 2009.
Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. Founded Regulus Therapeutics Inc. Announces U.S. Allowance Of Fundamental microRNA Therapeutics Patent Application
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the 'Esau' patent family (US Application Serial No. 10/909,125). The Esau patent estate, which is owned exclusively by Regulus, represents one of the earliest filings in the microRNA intellectual property landscape, and is fundamental to the discovery, development, and commercialization of microRNA therapeutics.
Isis Pharmaceuticals Announces Positive Phase 2 Data For ISIS 113715 In Patients With Type 2 Diabetes
Isis Pharmaceuticals announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control. In addition to lowering blood glucose, ISIS 113715 caused statistically significant and clinically meaningful reductions in LDL cholesterol. Consistent with the preclinical data with ISIS 113715, a tendency toward weight loss was observed even in this short-term study without strict dietary control. The effect of ISIS 113715 on weight was preceded by a statistically significant increase in circulating adiponectin, a hormone that is increased with weight loss. ISIS 113715 demonstrated a favorable safety profile with no exacerbation of sulfonylurea-induced hypoglycemia or other clinically significant adverse effects. The full details of the data will be presented at a future medical meeting. The analysis demonstrated statistically significant reductions in multiple indices of glucose control as compared to placebo in patients with type 2 diabetes on stable doses of sulfonylurea. Further, glycated albumin was also statistically significantly reduced and similar results were observed for fasting blood glucose.
Antisense Therapeutics Limited Announces Voting Power Of Isis Pharmaceuticals
Antisense Therapeutics Limited announced that Isis Pharmaceuticals has bought 58,808,333 ordinary shares of the Company representing 9.98% stake in the Company.
Alnylam Pharmaceuticals, Inc., Regulus Therapeutics Inc And Isis Pharmaceuticals Announce microRNA Patent Grant In Japan From Tuschl III Patent Series
Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, announced that the Japan Patent Office (JPO) has notified the Max Planck Society of its intent to grant a patent from the Tuschl III patent series (JP Application Number 2003-532675). This patent series pertains to the discovery of over 120 mammalian microRNAs, including miR-122, which is a pre-clinical program at Regulus. The grant of this first Tuschl III patent in Japan extends the scope of this patent estate, which has already yielded patents in the U.S. (U.S. Patent No. 7,232,806) and in Australia (Australian Patent No. 2002 347 035).
